WINSTON-SALEM, N.C., March 8, 2012 /PRNewswire/ -- Tengion, Inc. (NASDAQ: TNGN), a leader in regenerative medicine, today announced that A. Brian Davis, Chief Financial Officer and Vice President, Finance of Tengion, will present at the upcoming 24th Annual ROTH Investor Conference on Tuesday, March 13, 2012, at 3:00 p.m. PDT in Laguna Niguel, California.
A live audio webcast of the presentation can be accessed at http://wsw.com/webcast/roth26/tngn/ or under “Calendar of Events” in the Investors section of the Company’s website at www.tengion.com. A replay of the presentation will be available on Tengion’s website for 90 days. Investors interested in listening to the live webcast should log on before the start time in order to download any software required.
About Tengion
Tengion, a clinical-stage regenerative medicine company, is focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ. Using its Organ Regeneration Platform, the Company creates neo-organs using a patient’s own cells, or autologous cells. Tengion’s proprietary product candidates harness the intrinsic regenerative pathways of the body to regenerate a range of native-like organs and tissues. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications. An initial clinical trial is ongoing for the Company’s lead product candidate, the Neo-Urinary Conduit, an autologous implant that is intended to catalyze regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal. The Company’s lead preclinical candidate is the Neo-Kidney Augment, which is designed to prevent or delay dialysis by increasing renal function in patients with advanced chronic kidney disease. Tengion has worldwide rights to its product candidates.
SOURCE Tengion, Inc.
